SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Coherus Oncology Reports 75% Confirmed ORR in First-Line ESCC

Confirmed ORR was 100% among PD-L1-positive patients.

CHRS
SquawkNews Desk

Related stories

Silicom Q3 Revenue Jumps 71% Silicom said Q3 revenue rose 71% year over year. M impact | EQUITY | Oct 29, 2026, 12:26 PM UTC West Pharma executive says GLP-1 drugs helped drive growth in India and China A West Pharma executive said GLP-1 drugs helped drive growth in India and China, according to a conference call. M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC Luxshare Precision Q3 Net Profit Rises 6.98% Year Over Year M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC OMV Petrom Publishes Q3 2026 Results Presentation Transcript M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC Luxshare Precision Reports Q3 Revenue Up 14.6% Year Over Year Luxshare Precision said third-quarter revenue rose 14.6% year over year. M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC Luxshare Precision Says Q3 Revenue Rose 14.6% YoY Luxshare Precision said third-quarter revenue increased 14.6% year over year. M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC